 |
 |
|
When 50% of all drug delivery deals fail, how do you maximise your chance of success?Take advantage of a 1 hour free-of-charge consultation to discuss your key issues from finding the right partner, using your data to greatest effect through to understanding your technology's value. Utilise PharmaVentures expertise and knowledge to help you design, negotiate and implement successful transactions. Read more... or to discuss your needs in detail contact Mel Hemamda on +44 (0) 1865 784 177 or e-mail mel.hemamda@pharmaventures.com10% Pre-Publication offer on 'The Essential Guide to Partnering'This practical 'hands on' guide has been designed to help you successfully navigate the complex minefield of partnering. Read more...Due to be published in July 2005, this report provides a comprehensive insight into the rewards and challenges of the partnering process. To take advantage of this 10% pre-publication offer simply fill in the order form and make sure your order is received before the 16th June. |
||
 |
 |
 |
Market News and TrendsOne of the most significant drug delivery deals that was recorded in PharmaDeals® Agreements in May was between Neurologix Research and Medtronic. The deal is likely to result in improving the treatment of Parkinson's disease and temporal lobe epilepsy. The agreement, announced on May 2nd 2005, sets out plans for the two companies to jointly develop, manufacture and commercialise a micro-infusion catheter, designed to deliver a gene therapy based product into the brain and the central nervous system (CNS). The two companies will have agreed a revenue-sharing arrangement upon the commercialisation of the device. Read more... |
||
|
|
||
Featured ArticleOral Delivery of MacromoleculesChallenges exist that prevent the oral route from being utilised for macromolecular delivery due to the low oral bioavailability of proteins. Consequently, the scientific community has made a major thrust in recent years to overcome these obstacles to oral delivery through the development of a large number of new and innovative drug delivery techniques. These techniques are described by Kathryn Whitehead and Samir Mitragotri of the University of California, Santa Barbara. Read more... |
 |
||
|
|
||
 |
Company ProfilesControlled Therapeutics, Innovata, Pharmaceutical Profiles, Ypsomed |
||
|
|
||
Drug Delivery OpportunitiesView all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online.Featured Opportunity 7 day Transdermal Pain Patch Administrative route - Transdermal Indication - Relief of moderate-to-severe chronic pain for up to 7 days Licence code LO-0505-01 |
 |
||
|
|
||
 |
Autumn/Winter 2005 Drug Delivery ReportIf you are looking to complete a deal in 2005, then profiling your company in the Drug Delivery Report is a must. Relied upon as the main method of independently assessing drug delivery partners, it is read and accessed by senior decision makers within the Pharmaceutical and Biotech industry."The comprehensive listing for drug delivery companies makes it a key reference publication for those seeking drug delivery technology. Therefore, also an important place for us to be displayed." Dr Troels Keldmann, Managing Director, Direct-Haler A/S Find out about profiling your company in the forthcoming Autumn/Winter edition 2005. |
||
Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with clients to drive greater value from their deals.
If you do not wish to receive E-News in future, please email ddcr@pharmamail.biz with the words UNSUBSCRIBE as the subject.
If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddcr@pharmamail.biz with REMOVE as the subject.
For more details contact
Mel Hemamda, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@ddcr.com